Overview - Investors & Press - T2biosystems
T2Biosystems     Print Page | Close Window

Overview

Corporate Profile

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis SolutionTM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.23
Change (%) Stock is Up 0.11 (2.15%)
Volume168,828
Data as of 01/19/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
01/04/18T2 Biosystems Announces Preliminary Fourth Quarter 2017 Financial Results and Provides Update on T2Bacteria Panel
FDA Clearance of T2Bacteria® Panel remains on track for first quarter 2018 Total revenue expected to exceed the high end of guidance LEXINGTON, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and business results for the three months ended December 31, 2017 and provided an update on its 510(k) filing with the U.S. Food... 
Printer Friendly Version
11/27/17T2 Biosystems to Attend the Global Mizuho Investor Conference
LEXINGTON, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend the Global Mizuho Investor Conference (MIC). The conference is being held December 4-5, 2017 at the Lotte New York Palace Hotel in New York City wher... 
Printer Friendly Version
11/20/17T2 Biosystems Announces New T2Bacteria RUO Panel Data Presented at AMP 2017
Results Show Detection of Clinically Important Infections Missed by Blood Culture LEXINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced new data presented on the T2Sepsis Solution™ during the Association for Molecular Pathology (AMP) 2017 Conference in Salt Lake City, UT. These data highlight the potential clinical value that may be achieved us... 
Printer Friendly Version
11/09/17T2 Biosystems Announces Presentation on T2Sepsis Solution at AMP 2017
LEXINGTON, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced a workshop presentation on the T2Sepsis Solution™ during the Association for Molecular Pathology (AMP) 2017 Conference in Salt Lake City, UT on November 15. Attendees are also invited to visit T2 Biosystems at Booth #211 throughout the AMP Conference, where the Company will offer live demonstrat... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Chris Brinzey, Westwicke Partners chris.brinzey@westwicke.com
(339) 970-2843

Data provided by Nasdaq. Minimum 15 minutes delayed.